Alan Howard Hand, MD
Emergency Medicine · Sugar Land
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Hand’s office at (832) 640-4832 to ask if they take your plan before you enroll.
State licence records
1 licence
- Texas H4378Physician License · since 1988 · expires 2026-11-30ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Medicaid work
$1,379 in 2020
Medicaid paid $1,379 for 22 billed services this clinician did in 2020, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| EMERGENCY DEPT VISIT MOD MDM | 22 | $1,379 |
| 2020 | 22 | 1 | 20 | $1,379 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Daiichi Sankyo Company LTD · Ds7011-A-U101 · 2023 | Their institution | $2,451,135 |
| SK Life Science, Inc. · Ykp3089c045 · 2023 | Their institution | $1,230,752 |
| Daiichi Sankyo Company LTD · Ds7011-A-U101 · 2022 | Their institution | $1,159,225 |
| E.R. Squibb & Sons, L.L.C. · A Phase 1 Randomized, Doubleblind, Positivecontrolled, Placebocontrolled, 4period Crossover, Thorough Qt/Qtc Study To Evaluate the Effect of Multiple Doses of Bms986278 on Cardiac Repolarization in Healthy Participants · 2025 | Their institution | $741,514 |
| Daiichi Sankyo Company LTD · Ds7011-A-U101 · 2024 | Their institution | $367,479 |
| SK Life Science, Inc. · Ykp3089c045 · 2024 | Their institution | $284,335 |
| SK Life Science, Inc. · Ykp3089c045 · 2022 | Their institution | $233,935 |
| E.R. Squibb & Sons, L.L.C. · Relative Ba (Open Capsule, Ng Tube) - An Open-Label, Randomized, Single-Dose, Three-Way Crossover Study To Assess the Relative Bioavailability of 5 Mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared To 5 Mg Mavacamten Intact Capsule I · 2024 | Their institution | $211,045 |
| Daiichi Sankyo Company LTD · Ds7011-A-U101 · 2021 | Their institution | $75,000 |
| E.R. Squibb & Sons, L.L.C. · An Open-Label, Randomized, Single-Dose, Three-Way Crossover Study To Assess the Relative Bioavailability of 5 Mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared To 5 Mg Mavacamten Intact Capsule in Healthy Participants · 2025 | Their institution | $5,649 |
| Eli Lilly and Company · A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of Ly3885125 To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Ascending Dose in Participants With Dyslipidemia and Repeat-Doses in Participants With Nafld · 2024 | This clinician | $246 |
| Eli Lilly and Company · A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of Ly3885125 To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Ascending Dose in Participants With Dyslipidemia and Repeat-Doses in Participants With Nafld · 2024 | Their institution | $33 |
Professional record
- NPI
- 1851391114
- Licence
- TX H4378Texas H4378: Active
More record details
- Sole proprietor
- No
- Medicaid ID
- TX 140258801
- Taxonomy
- Federal specialty code 207P00000X (207P00000X)
- Mailing address
- 10 Ellicott Way, Sugar Land, TX, 77479
- NPI first listed
- 2005-07-28
- NPI last updated
- 2011-04-18
This is when the NPI record was last certified, not a medical board exam.